CRISPR/Cas9 Genomics, Research & Insights

ERS Genomics & Demeetra Enter Into CRISPR/Cas9 Licensing Agreement

ERS Genomics & Demeetra Enter Into CRISPR/Cas9 Licensing Agreement Demeetra to broaden synthetic biology and bioprocessing technology through combined CRISPR/Cas9 IP and Demeetra’s own dimeric…

14 September 2023 7:55·

ERS Genomics & AlgenScribe Enter Into CRISPR/Cas9 Licensing Agreement

ERS Genomics & AlgenScribe Enter Into CRISPR/Cas9 Licensing Agreement License allows AlgenScribe to expand its research and development activities using CRISPR/Cas9. Dublin, Ireland and Nice,…

5 September 2023 8:39·

ERS Genomics & Santa Cruz Biotechnology Enter Into CRISPR/Cas9 Licensing Agreement

License allows Santa Cruz Biotechnology to develop and commercialize products using CRISPR/Cas9. Dublin, Ireland and Dallas, Texas, 10 August 2023: ERS Genomics Limited (‘ERS’) is…

10 August 2023 8:01·

Reflections on BIO International

Over 20,000 Participants & A Lot to Talk About: Reflecting on Bio International Convention, Boston 2023.

3 August 2023 15:27·

ERS Genomics & Transomic Technologies enter into CRISPR/Cas9 Licensing Agreement

License allows Transomic Technologies to develop and commercialize products using CRISPR/Cas9. Dublin, Ireland and Huntsville, AL, USA, August 3, 2023: ERS Genomics Limited (‘ERS’) is…

3 August 2023 8:00·

Manipulating the Fabric of Life

Someone’s famous uncle once said, “With great power comes great responsibility.” Genome editing is an incredibly powerful technique with huge promise and potential for medicine,…

24 July 2023 10:17·

SynBioBeta 2023

SynBioBeta 2023 With ERS’ Paul Carter – Sr. Director Business Development & Licensing, North America https://ersgenomics.com/wp-content/uploads/2023/06/Paul-Carter-SynBioBeta-audiogram.mp4 SynBioBeta 2023: Time to scale The recent SynBioBeta conference…

23 June 2023 13:00·

ERS Genomics & abm enter into CRISPR/Cas9 Licensing Agreement

ERS Genomics & abm enter into CRISPR/Cas9 Licensing Agreement This License allows abm to develop and commercialize products using CRISPR/Cas9 technology. Dublin, Ireland and Vancouver,…

1 June 2023 7:55·

LSPN Boston 2023: Life Science IP Review

“Although CVC and Broad’s CRISPR/Cas9 gene editing patents currently coexist in the US, pending federal circuit appeal, the picture is clearer in the EPO opposition…

11 May 2023 9:23·

Knowledge Centre